The role of central histamine receptor blockers in the treatment of insomnia

Strigin K.N.

doi:https://doi.org/10.17116/jnevro20181184273

Strigin K.N.

Sechenov First Moscow State Medical University, Moscow, Russia

The role of central histamine receptor blockers in the treatment of insomnia

Authors:

Strigin K.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4‑2): 73‑82

DOI: 10.17116/jnevro20181184273

Read: 10983 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Strigin KN. The role of central histamine receptor blockers in the treatment of insomnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4‑2):73‑82. (In Russ.)
https://doi.org/10.17116/jnevro20181184273

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Stress and sleep: Neurobiological aspects and modern options of insomnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21

Factors of depression according to actigraphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32

Insomnia in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):46-51

The use of zolpidem in the treatment of acute and chronic insomnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):52-56

The potential of neurofeedback control in treating insomnia and improving sleep quality (a systematic review). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):57-63

Effects of rhythmic transcranial magnetic stimulation in the treatment of insomnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):64-69

Sleep disorders in imprinting disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):75-80

Sleep disorders in patients with Lewy body dementia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87

Sleep deprivation and the development of oxidative stress in animal models. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):124-129

The state of mental health of migrant workers and citizens of the Russian Federation: A comparative analysis as illustrated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101

Abstract:

The article analyzes the anatomy, morphological and neurochemical connections and functions of the brain histaminergic system, one of the leading systems in the mechanism maintaining wakefulness. The possibilities of histaminergic system modulating for the treatment of various sleep/wake cycle disorders are discussed. The data of clinical trials on the influence of the histamine H1 receptor antagonist doxylamine on sleep in healthy volunteers and patients with insomnia are considered. The evidence-based efficacy of the drug in sleep disorders is discussed.

Keywords:

sleep

histamine

doxylamine

donormyl

insomnia

Authors:

Strigin K.N.

Sechenov First Moscow State Medical University, Moscow, Russia

Close metadata

References:

American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
Kovalzan VM. The role of the histaminergic system of the brain in the regulation of the wakefulness-sleep cycle. Humanphysiology. 2013;39(6):13-23. (In Russ.)
Kovalson VМ, Strygin KN. Neurochemical mechanisms of sleep and wakefulness regulation: the role of histamine receptor blockers in the treatment of insomnia. Effective pharmacotherapy (Specialist. Issue «Sleep and its frustration»). 2013;12:8-15. (In Russ.)
Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci. 2003;4:121.
Gene M, Smith GM, Porter H, Smith PH. Effects of doxylamine and acetaminophen on postoperative sleep. Clinpharmacol Ther. 1985;37(5):549-557.
Hausser-Hauw C, Fleury B, Scheck F, Pello JY, Lebeau B. Effect on sleep architecture and residual effect of a dose of 15 mg of Doxylamine in healthy volunteers. Sep Hop Paris. 1995;71:(23-24):742-750.
Schadeck B, Chelly M, Amsellem D, Cohen A, Peraudeau P, Scheck F. Comparative efficacy of doxylamine and zolpidem for the treatment of common insomnia. Sep Hop Paris. 1996;72(13-14):428-439.
Wein AM. Report on Donormil’s study in patients with insomnia. M.: Center for somnological research; 1997. (In Russ.)
Levin YaI, Strygin KN. Donormil in therapy of insomnia. Treatment of nervous diseases. 2005;6(2):23-26. (In Russ.)
Levin YaI, Eligulashvili TS, Posokhov SI, Kovrov GV, Bashmakov MYu. Farmakoterapiyainsomnii: rol’ Imovana. V kn.: Rasstroistva sna. Pod red. Aleksandrovskogo YuA i Veina AM. SPb.: Meditsinskoe informatsionnoe agenstvo; 1995. (In Russ.)
Rechtchaffen A, Kales A. A manual of standartized terminology, techniques and scoring for sleep stages of human subjects. Bethesda, Washington D.C. U.S.: Government Priting office; 1968.
Smulevich AB, Zheleznova MV, Pavlova LK. The use of the drug «Donormil» in the treatment of sleep disorders of medium and mild severity in the practice of a psychiatrist. Psychiatry and psychopharmacotherapy. 2006;8(1):12-17. (In Russ.)
Gustov AV, Smirnov AA, Zheltova OYu. Efficacy of donormyl in the treatment of insomnia in patients with dyscirculatory encephalopathy. Journal neurology and psychiatry im. S.S. Korsakov. 2006;106(3):64. (In Russ.)
Adamenko R.YA. Lechenie insomnii u bol’nyh hronicheskoj nedostatochnost’yu mozgovogo krovoobrashcheniya. Zhurnal prakticheskogo vracha. 2001;5:45-51. (In Russ.)
accessed May 22, 2018]. https://www.researchgate.net/publication/236599819 (In Russ.)